Epidemiology and prevention of stroke: A worldwide perspective

Expert Review of Neurotherapeutics

Volumn 12, Issue 2, 2012, Pages 199-208

  Kuklina, Elena V ^a   Tong, Xin ^a   George, Mary G ^a   Bansil, Pooja ^a  

^a NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

Author keywords

anticoagulation therapy; antihypertensive therapy; antiplatelet therapy; risk factors; statins; stroke

Indexed keywords

LIPID;

ALCOHOL CONSUMPTION; CARDIOVASCULAR DISEASE; CIGARETTE SMOKING; DEPRESSION; DIABETES MELLITUS; DIET; DYSLIPIDEMIA; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; IMMOBILIZATION; MEDLINE; MENTAL STRESS; MORTALITY; OBESITY; PHYSICAL ACTIVITY; REVIEW; RISK FACTOR; SMOKING; STROKE;

ATRIAL FIBRILLATION; HUMANS; HYPERTENSION; LIFE STYLE; OBESITY; PREVALENCE; RISK FACTORS; SMOKING; STROKE;

EID: 84856605923     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.11.99     Document Type: Review

References (102)

1. Strong K, Mathers C, Bonita R. Preventing stroke: saving lives around the world. Lancet Neurol. 6(2), 182-187 (2007). (Pubitemid 46097543)
2. WHO. The Global Burden of Disease: 2004 Update. WHO, Geneva, Switzerland (2008).
3. O'Donnell MJ, Xavier D, Liu L, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet 376(9735), 112-123 (2010).
4. Goldstein LB, Bushnell CD, Adams RJ, et al. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 42(2), 517-584 (2011).
5. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 338, b1665 (2009).
6. Sharma M, Hakim AM. The management of hypertension for primary stroke prevention: a proposed approach. Int. J. Stroke 6(2), 144-149 (2011).
7. Arguedas JA. Blood pressure targets: are clinical guidelines wrong? Curr. Opin. Cardiol. 25(4), 350-354 (2010).
8. Arguedas JA, Perez MI, Wright JM. Treatment blood pressure targets for hypertension. Cochrane Database Syst. Rev. 3, CD004349 (2009).
9. Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in Type 2 diabetes mellitus. N. Engl. J. Med. 362(17), 1575-1585 (2010).
10. Bangalore S, Kumar S, Lobach I, Messerli FH. Blood pressure targets in subjects with Type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials. Circulation 123(24), 2799-2810 (2011).
11. Ovbiagele B, Diener HC, Yusuf S, et al. Level of systolic blood pressure within the normal range and risk of recurrent stroke. JAMA 306(19), 2137-2144 (2011).
12. Cooper-DeHoff RM, Gong Y, Handberg EM, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 304(1), 61-68 (2010).
13. Mancia G, Schumacher H, Redon J, et al. Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET). Circulation 124(16), 1727-1736 (2011).
14. Thompson AM, Hu T, Eshelbrenner CL, Reynolds K, He J, Bazzano LA. Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysis. JAMA 305(9), 913-922 (2011).
15. Bejan-Angoulvant T, Saadatian-Elahi M, Wright JM, et al. Treatment of hypertension in patients 80 years and older: the lower the better? A meta-analysis of randomized controlled trials. J. Hypertens. 28(7), 1366-1372 (2010).
16. Messerli FH, Panjrath GS. The J-curve between blood pressure and coronary artery disease or essential hypertension: exactly how essential? J. Am. Coll. Cardiol. 54(20), 1827-1834 (2009).
17. Chrysant SG, Chrysant GS. Effectiveness of lowering blood pressure to prevent stroke versus to prevent coronary events. Am. J. Cardiol. 106(6), 825-829 (2010).
18. Di Angelantonio E, Sarwar N, Perry P, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302(18), 1993-2000 (2009).
19. Canoui-Poitrine F, Luc G, Bard JM, et al. Relative contribution of lipids and apolipoproteins to incident coronary heart disease and ischemic stroke: the PRIME Study. Cerebrovasc. Dis. 30(3), 252-259 (2010).
20. Imamura T, Doi Y, Arima H, et al. LDL cholesterol and the development of stroke subtypes and coronary heart disease in a general Japanese population: the Hisayama study. Stroke 40(2), 382-388 (2009).
21. Athyros VG, Tziomalos K, Karagiannis A, Wierzbicki AS, Mikhailidis DP. Aggressive statin treatment, very low serum cholesterol levels and haemorrhagic stroke: is there an association? Curr. Opin. Cardiol. 25(4), 406-410 (2010).
22. Genser B, Marz W. Low density lipoprotein cholesterol, statins and cardiovascular events: a meta-analysis. Clin. Res. Cardiol. 95(8), 393-404 (2006). (Pubitemid 44133990)
23. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376(9753), 1670-1681 (2010).
24. De Caterina R, Scarano M, Marfisi R, et al. Cholesterol-lowering interventions and stroke: insights from a meta-analysis of randomized controlled trials. J. Am. Coll. Cardiol. 55(3), 198-211 (2010).
25. Fuentes B, Martinez-Sanchez P, Diez-Tejedor E. Lipid-lowering drugs in ischemic stroke prevention and their influence on acute stroke outcome. Cerebrovasc. Dis. 27(Suppl. 1), 126-133 (2009).
26. Abourbih S, Filion KB, Joseph L, et al. Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review. Am. J. Med. 122(10), 962, e961-e968 (2009).
27. Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 375(9729), 1875-1884 (2010).
28. Saha SA, Arora RR. Fibrates in the prevention of cardiovascular disease in patients with Type 2 diabetes mellitus -a pooled meta-analysis of randomized placebo-controlled clinical trials. Int. J. Cardiol. 141(2), 157-166 (2009).
29. Bruckert E, Labreuche J, Deplanque D, Touboul PJ, Amarenco P. Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis. J. Cardiovasc. Pharmacol. 57(2), 267-272 (2011).
30. Chirovsky DR, Fedirko V, Cui Y, Sazonov V, Barter P. Prospective studies on the relationship between high-density lipoprotein cholesterol and cardiovascular risk: a systematic review. Eur. J. Cardiovasc. Prev. Rehabil. 16(4), 404-423 (2009).
31. Sarwar N, Gao P, Seshasai SR, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 375(9733), 2215-2222 (2010).
32. Spellman CW. Achieving glycemic control: cornerstone in the treatment of patients with multiple metabolic risk factors. J. Am. Osteopath. Assoc. 109(5 Suppl.), S8-S13 (2009).
33. Brown A, Reynolds LR, Bruemmer D. Intensive glycemic control and cardiovascular disease: an update. Nat. Rev. Cardiol. 7(7), 369-375 (2010).
34. Reboldi G, Gentile G, Angeli F, Verdecchia P. Optimal therapy in hypertensive subjects with diabetes mellitus. Curr. Atheroscler. Rep. 13(2), 176-185 (2011).
35. Lip GY, Boos CJ. Antithrombotic treatment in atrial fibrillation. Postgrad. Med. J. 84(991), 252-258 (2008). (Pubitemid 351839232)
36. Iwahana H, Ishikawa S, Ishikawa J, et al. Atrial fibrillation is a major risk factor for stroke, especially in women: the Jichi Medical School Cohort Study. J. Epidemiol. 21(2) 95-101 (2011).
37. Lip GY, Rudolf M, Kakar P. Management of atrial fibrillation: the NICE guidelines. Int. J. Clin. Pract. 61(1), 9-11 (2007).
38. Perez A, Touchette DR, Didomenico RJ, Stamos TD, Walton SM. Comparison of rate control versus rhythm control for management of atrial fibrillation in patients with coexisting heart failure: a cost-effectiveness analysis. Pharmacotherapy 31(6), 552-565 (2011).
39. Lip GY, Halperin JL, Tse HF. The 2010 European Society of Cardiology Guidelines on the management of atrial fibrillation: an evolution or revolution? Chest 139(4), 738-741 (2011).
40. Moubarak G. Evolution of the strength of recommendations in guidelines for the management of atrial fibrillation. Int. J. Cardiol. 149(3), 394-395 (2011).
41. Stiell IG, Macle L. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: management of recent-onset atrial fibrillation and flutter in the emergency department. Can. J. Cardiol. 27(1), 38-46 (2011).
42. Fuster V, Ryden LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 123(10), e269-e367 (2011).
43. Tzeis S, Andrikopoulos G. Novel anticoagulants for atrial fibrillation: a critical appraisal. Angiology doi:10.1177/0003319711422808 (2011) (Epub ahead of print).
44. Jackson G. Tobacco: the most important preventable cause of cardiovascular disease. Int. J. Clin. Pract. 64(3), 279-280 (2010).
45. Girot M. [Smoking and stroke]. Presse Med. 38(7-8), 1120-1125 (2009).
46. O'Donnell M, Yusuf S. Tackling the global burden of stroke: the need for large-scale international studies. Lancet Neurol .8(4), 306-307 (2009).
47. Bhat VM, Cole JW, Sorkin JD, et al. Dose-response relationship between cigarette smoking and risk of ischemic stroke in young women. Stroke 39(9), 2439-2443 (2008).
48. Truelsen T. Advances in population-based studies. Stroke 41(2), e99-e101 (2010).
49. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ 328(7455), 1519 (2004).
50. Lee PN, Forey BA. Environmental tobacco smoke exposure and risk of stroke in nonsmokers: a review with meta-analysis. J. Stroke Cerebrovasc. Dis. 15(5), 190-201 (2006). (Pubitemid 44332973)
51. Strazzullo P, D'Elia L, Cairella G, Garbagnati F, Cappuccio FP, Scalfi L. Excess body weight and incidence of stroke: meta-analysis of prospective studies with 2 million participants. Stroke 41(5), e418-e426 (2010).
52. Yatsuya H, Folsom AR, Yamagishi K, North KE, Brancati FL, Stevens J. Race-and sex-specific associations of obesity measures with ischemic stroke incidence in the Atherosclerosis Risk in Communities (ARIC) study. Stroke 41(3), 417-425 (2010).
53. Yatsuya H, Yamagishi K, North KE, Brancati FL, Stevens J, Folsom AR. Associations of obesity measures with subtypes of ischemic stroke in the ARIC Study. J. Epidemiol. 20(5), 347-354 (2010).
54. Vemmos K, Ntaios G, Spengos K, et al. Association between obesity and mortality after acute first-ever stroke: the obesity-stroke paradox. Stroke 42(1), 30-36 (2010).
55. Sanchez-Moreno C, Jimenez-Escrig A, Martin A. Stroke: roles of B vitamins, homocysteine and antioxidants. Nutr. Res. Rev. 22(1), 49-67 (2009).
56. Schurks M, Glynn RJ, Rist PM, Tzourio C, Kurth T. Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials. BMJ 341, c5702 (2010).
57. Micha R, Mozaffarian D. Saturated fat and cardiometabolic risk factors, coronary heart disease, stroke, and diabetes: a fresh look at the evidence. Lipids 45(10), 893-905 (2010).
58. Siri-Tarino PW, Sun Q, Hu FB, Krauss RM. Meta-analysis of prospective cohort studies evaluating the association of saturated fat with cardiovascular disease. Am. J. Clin. Nutr. 91(3), 535-546 (2010).
59. Yamagishi K, Iso H, Yatsuya H, et al. Dietary intake of saturated fatty acids and mortality from cardiovascular disease in Japanese: the Japan Collaborative Cohort Study for Evaluation of Cancer Risk (JACC) Study. Am. J. Clin. Nutr. 92(4), 759-765 (2010).
60. He FJ, MacGregor GA. A comprehensive review on salt and health and current experience of worldwide salt reduction programmes. J. Hum. Hypertens. 23(6), 363-384 (2009).
61. Strazzullo P, D'Elia L, Kandala NB, Cappuccio FP. Salt intake, stroke, and cardiovascular disease: meta-analysis of prospective studies. BMJ 339, b4567 (2009).
62. Agnoli C, Krogh V, Grioni S, et al. A priori-defined dietary patterns are associated with reduced risk of stroke in a large italian cohort. J. Nutr. doi:10.3945/jn.111.140061 (2011) (Epub ahead of print).
63. Liang W, Lee AH, Binns CW. Tea drinking, diet and ischemic stroke prevention in China: a future perspective. Expert Rev. Cardiovasc. Ther. 7(11), 1447-1454 (2009).
64. Buitrago-Lopez A, Sanderson J, Johnson L, et al. Chocolate consumption and cardiometabolic disorders: systematic review and meta-analysis. BMJ 343, d4488 (2011).
65. He FJ, Nowson CA, MacGregor GA. Fruit and vegetable consumption and stroke: meta-analysis of cohort studies. Lancet 367(9507), 320-326 (2006). (Pubitemid 43151465)
66. Scarborough P, Nnoaham KE, Clarke D, Capewell S, Rayner M. Modelling the impact of a healthy diet on cardiovascular disease and cancer mortality. J. Epidemiol. Community Health doi:10.1136/jech.2010.114520 (2010) (Epub ahead of print).
67. Stamler J. Diet-heart: a problematic revisit. Am. J. Clin. Nutr. 91(3), 497-499 (2010).
68. Klatsky AL. Alcohol and cardiovascular health. Physiol. Behav. 100(1), 76-81 (2010).
69. Feigin VL, Rinkel GJ, Lawes CM, et al. Risk factors for subarachnoid hemorrhage: an updated systematic review of epidemiological studies. Stroke 36(12), 2773-2780 (2005).
70. Sull JW, Yi SW, Nam CM, Choi K, Ohrr H. Binge drinking and hypertension on cardiovascular disease mortality in Korean men and women: a Kangwha cohort study. Stroke 41(10), 2157-2162 (2010).
71. Guiraud V, Amor MB, Mas JL, Touze E. Triggers of ischemic stroke: a systematic review. Stroke 41(11), 2669-2677 (2010).
72. Ronksley PE, Brien SE, Turner BJ, Mukamal KJ, Ghali WA. Association of alcohol consumption with selected cardiovascular disease outcomes: a systematic review and meta-analysis. BMJ 342, d671 (2011).
73. Diep L, Kwagyan J, Kurantsin-Mills J, Weir R, Jayam-Trouth A. Association of physical activity level and stroke outcomes in men and women: a meta-analysis. J. Womens Health (Larchmt) 19(10), 1815-1822 (2010).
74. Carnethon MR. Physical activity and cardiovascular disease: how much is enough? Am. J. Lifestyle Med. 3(1 Suppl.), 44S-49S (2009).
75. Boysen G, Krarup LH. Benefits of physical activity for stroke survivors. Expert Rev. Neurother. 9(2), 147-149 (2009).
76. Hackett ML, Yapa C, Parag V, Anderson CS. Frequency of depression after stroke: a systematic review of observational studies. Stroke 36(6), 1330-1340 (2005). (Pubitemid 40798764)
77. Van der Kooy K, van Hout H, Marwijk H, Marten H, Stehouwer C, Beekman A. Depression and the risk for cardiovascular diseases: systematic review and meta analysis. Int. J. Geriatr. Psychiatry 22(7), 613-626 (2007). (Pubitemid 47180373)
78. Pan A, Sun Q, Okereke OI, Rexrode KM, Hu FB. Depression and risk of stroke morbidity and mortality: a meta-analysis and systematic review. JAMA 306(11), 1241-1249 (2011).
79. Salaycik KJ, Kelly-Hayes M, Beiser A, et al. Depressive symptoms and risk of stroke: the Framingham Study. Stroke 38(1), 16-21 (2007). (Pubitemid 46035600)
80. Liebetrau M, Steen B, Skoog I. Depression as a risk factor for the incidence of first-ever stroke in 85-year-olds. Stroke 39(7), 1960-1965 (2008).
81. Arbelaez JJ, Ariyo AA, Crum RM, Fried LP, Ford DE. Depressive symptoms, inflammation, and ischemic stroke in older adults: a prospective analysis in the cardiovascular health study. J. Am. Geriatr. Soc. 55(11), 1825-1830 (2007). (Pubitemid 350043768)
82. Peters R, Pinto E, Beckett N, et al. Association of depression with subsequent mortality, cardiovascular morbidity and incident dementia in people aged 80 and over and suffering from hypertension. Data from the Hypertension in the Very Elderly Trial (HYVET). Age Ageing 39(4), 439-445 (2010).
83. Kamphuis MH, Geerlings MI, Giampaoli S, Nissinen A, Grobbee DE, Kromhout D. The association of depression with cardiovascular mortality is partly explained by health status. The FINE Study. J. Affect. Disord. 114(1-3), 184-192 (2009).
84. Smoller JW, Allison M, Cochrane BB, et al. Antidepressant use and risk of incident cardiovascular morbidity and mortality among postmenopausal women in the Women's Health Initiative study. Arch. Intern. Med. 169(22), 2128-2139 (2009).
85. Hamer M, Molloy GJ, Stamatakis E. Psychological distress as a risk factor for cardiovascular events: pathophysiological and behavioral mechanisms. J. Am. Coll. Cardiol. 52(25), 2156-2162 (2008).
86. Tsutsumi A, Kayaba K, Kario K, Ishikawa S. Prospective study on occupational stress and risk of stroke. Arch. Intern. Med. 169(1), 56-61 (2009).
87. Surtees PG, Wainwright NW, Luben RN, Wareham NJ, Bingham SA, Khaw KT. Psychological distress, major depressive disorder, and risk of stroke. Neurology 70(10), 788-794 (2008).
88. Ohira T. Psychological distress and cardiovascular disease: the Circulatory Risk in Communities Study (CIRCS). J. Epidemiol. 20(3), 185-191 (2010).
89. Jood K, Redfors P, Rosengren A, Blomstrand C, Jern C. Self-perceived psychological stress and ischemic stroke: a case-control study. BMC Med. 7, 53 (2009).
90. May M, McCarron P, Stansfeld S, et al. Does psychological distress predict the risk of ischemic stroke and transient ischemic attack? The Caerphilly Study. Stroke 33(1), 7-12 (2002). (Pubitemid 34052175)
91. Smith SCJ, Zheng ZJ. The impending cardiovascular pandemic in China. Circ. Cardiovasc. Qual. Outcomes 3(3), 226-227 (2010).
92. Moran A, Gu D, Zhao D, et al. Future cardiovascular disease in china: markov model and risk factor scenario projections from the coronary heart disease policy model -China. Circ. Cardiovasc. Qual. Outcomes 3(3), 243-252 (2010).
93. He J, Gu D, Wu X, et al. Major causes of death among men and women in China. N. Engl. J. Med. 353(11), 1124-1134 (2005). (Pubitemid 41317435)
94. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 367(9524), 1747-1757 (2006). (Pubitemid 43767064)
95. Li H, Meng Q, Sun X, Salter A, Briggs NE, Hiller JE. Prevalence, awareness, treatment, and control of hypertension in rural China: results from Shandong Province. J. Hypertens. 28(3), 432-438 (2010).
96. Pang W, Li Z, Sun Z, et al. Prevalence of hypertension and associated factors among older rural adults: results from Liaoning Province, China. Med. Princ. Pract. 19(1), 22-27 (2010).
97. Joshi R, Jan S, Wu Y, MacMahon S. Global inequalities in access to cardiovascular health care: our greatest challenge. J. Am. Coll. Cardiol. 52(23), 1817-1825 (2008).
98. Wang X, Jiang G, Choi BC, et al. Surveillance of trend and distribution of stroke mortality by subtype, age, gender, and geographic areas in Tianjin, China, 1999-2006. Int. J. Stroke 4(3), 169-174 (2009).
99. Jekal Y, Yun JE, Park SW, Jee SH, Jeon JY. The relationship between the level of fatness and fitness during adolescence and the risk factors of metabolic disorders in adulthood. Korean Diabetes J. 34(2), 126-134 (2010).
100. Juonala M, Viikari JS, Kahonen M, et al. Life-time risk factors and progression of carotid atherosclerosis in young adults: the Cardiovascular Risk in Young Finns study. Eur. Heart J. 31(14), 1745-1751 (2010).
101. Howard VJ, Woolson RF, Egan BM, et al. Prevalence of hypertension by duration and age at exposure to the stroke belt. J. Am. Soc. Hypertens. 4(1), 32-41 (2010).
102. Sacco R, Smith S, Holmes D, et al. Accelerating progress on non-communicable diseases. Lancet doi:10.1016/S0140-6736(11)61477-3 (2011) (Epub ahead of print).